



Clinical trial results:

Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease Progression

Summary

EudraCT number	2015-000396-26
Trial protocol	Outside EU/EEA
Global end of trial date	16 February 2011

Results information

Result version number	v1 (current)
This version publication date	22 March 2016
First version publication date	05 August 2015

Trial information

Trial identification

Sponsor protocol code	EA-US-205-0111
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00499720
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Clinical Trial Mailbox, Gilead Sciences International Ltd, ClinicalTrialDisclosures@gilead.com
Scientific contact	Clinical Trial Mailbox, Gilead Sciences International Ltd, ClinicalTrialDisclosures@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 February 2011
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	16 February 2011
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation 75 mg prior to its commercial availability to patients with cystic fibrosis and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	28 September 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 605
Worldwide total number of subjects	605
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	19
Adolescents (12-17 years)	89

Adults (18-64 years)	495
From 65 to 84 years	2
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at sites in the United States. The first participant was screened on 28 September 2007. The last study visit occurred on 16 February 2011.

Pre-assignment

Screening details:

626 potential participants were screened.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All participants
------------------	------------------

Arm description:

Aztreonam for inhalation solution (AZLI) 3 times daily in 56-day cycles (28 days on treatment followed by 28 days off treatment).

Arm type	Experimental
Investigational medicinal product name	Aztreonam for inhalation solution
Investigational medicinal product code	
Other name	AZLI, Cayston®
Pharmaceutical forms	Powder for nebuliser solution
Routes of administration	Inhalation use

Dosage and administration details:

AZLI 75 mg administered 3 times daily using the eFlow nebulizer

Number of subjects in period 1^[1]	All participants
Started	603
Completed	259
Not completed	344
Not specified	124
Participant request to discontinue	164
Pregnancy	2
Investigator discretion, intercurrent illness	10
Participant noncompliance	44

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Two participants who were enrolled but not treated are not included in the subject disposition table.

Baseline characteristics

Reporting groups

Reporting group title	All participants
-----------------------	------------------

Reporting group description:

Aztreonam for inhalation solution (AZLI) 3 times daily in 56-day cycles (28 days on treatment followed by 28 days off treatment).

Reporting group values	All participants	Total	
Number of subjects	603	603	
Age categorical			
Units: Subjects			
Age continuous			
Units: years			
arithmetic mean	28.8		
standard deviation	± 11.68	-	
Gender categorical			
Units: Subjects			
Female	314	314	
Male	289	289	
Race			
Units: Subjects			
African American	7	7	
Hispanic	18	18	
White	576	576	
Other	2	2	
FEV1 % predicted			
FEV1 % predicted is defined as FEV1 % of the patient divided by the average FEV1 % in the population for any person of similar age, sex and body composition. The mean/standard deviation (SD) for the number of participants with available baseline data are reported (n = 599).			
Units: percentage of FEV1 % predicted			
arithmetic mean	40.37		
standard deviation	± 16.13	-	

End points

End points reporting groups

Reporting group title	All participants
Reporting group description: Aztreonam for inhalation solution (AZLI) 3 times daily in 56-day cycles (28 days on treatment followed by 28 days off treatment).	

Primary: Percentage of participants experiencing any serious adverse event

End point title	Percentage of participants experiencing any serious adverse event ^[1]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From date of first dose to study discontinuation (average 61 weeks) plus 30 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned or performed.

End point values	All participants			
Subject group type	Reporting group			
Number of subjects analysed	603			
Units: percentage of participants				
number (not applicable)	58.5			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

From date of first dose to study discontinuation (average 61 weeks) plus 30 days

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

Reporting groups

Reporting group title	All participants
-----------------------	------------------

Reporting group description:

Aztreonam for inhalation solution (AZLI) 3 times daily in 56-day cycles (28 days on treatment followed by 28 days off treatment).

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Per protocol, non-serious adverse events were not collected in this expanded access study.

Serious adverse events	All participants		
Total subjects affected by serious adverse events			
subjects affected / exposed	353 / 603 (58.54%)		
number of deaths (all causes)	33		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Arterial haemorrhage			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Deep vein thrombosis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Antibiotic prophylaxis			

subjects affected / exposed	4 / 603 (0.66%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Antibiotic therapy			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune tolerance induction			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	3 / 603 (0.50%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Medical device complication			
subjects affected / exposed	2 / 603 (0.33%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Catheter site pain			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Influenza like illness			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Medical device pain			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombosis in device			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Liver transplant rejection			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Lung disorder			

subjects affected / exposed	301 / 603 (49.92%)		
occurrences causally related to treatment / all	1 / 756		
deaths causally related to treatment / all	0 / 11		
Haemoptysis			
subjects affected / exposed	31 / 603 (5.14%)		
occurrences causally related to treatment / all	1 / 38		
deaths causally related to treatment / all	0 / 3		
Pneumonia			
subjects affected / exposed	14 / 603 (2.32%)		
occurrences causally related to treatment / all	0 / 14		
deaths causally related to treatment / all	0 / 2		
Infective pulmonary exacerbation of cystic fibrosis			
subjects affected / exposed	12 / 603 (1.99%)		
occurrences causally related to treatment / all	0 / 14		
deaths causally related to treatment / all	0 / 2		
Pneumothorax			
subjects affected / exposed	10 / 603 (1.66%)		
occurrences causally related to treatment / all	0 / 12		
deaths causally related to treatment / all	0 / 1		
Respiratory failure			
subjects affected / exposed	7 / 603 (1.16%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 2		
Chronic sinusitis			
subjects affected / exposed	6 / 603 (1.00%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Cystic fibrosis lung			
subjects affected / exposed	5 / 603 (0.83%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 3		
Acute respiratory failure			

subjects affected / exposed	4 / 603 (0.66%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 2			
Bronchopneumonia				
subjects affected / exposed	3 / 603 (0.50%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Pneumonia bacterial				
subjects affected / exposed	3 / 603 (0.50%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Bronchiectasis				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Respiratory distress				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 1			
Acute sinusitis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cystic fibrosis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dyspnoea				

subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Lobar pneumonia			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection bacterial			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung infection pseudomonal			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pulmonary vasculitis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sinus disorder			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sinus polyp			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Depression			

subjects affected / exposed	2 / 603 (0.33%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Suicidal ideation			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Weight decreased			
subjects affected / exposed	2 / 603 (0.33%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pulmonary function test decreased			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Toxicity to various agents			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardio-respiratory arrest			
subjects affected / exposed	3 / 603 (0.50%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 3		
Atrial thrombosis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Nervous system disorders			
Embolic stroke			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Hepatic encephalopathy			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemolytic anaemia			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Splenomegaly			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Small intestinal obstruction			
subjects affected / exposed	8 / 603 (1.33%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
Distal intestinal obstruction syndrome			
subjects affected / exposed	4 / 603 (0.66%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Distal ileal obstruction syndrome			

subjects affected / exposed	3 / 603 (0.50%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Abdominal pain				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Gastritis				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Gastroesophageal reflux disease				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 2			
Pancreatitis acute				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Abdominal pain lower				

subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Aphthous stomatitis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Faecaloma				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal hypomotility				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrooesophagitis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haematemesis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haematochezia				

subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis chronic			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis relapsing			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal haemorrhage			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Portal hypertension			

subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	5 / 603 (0.83%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	3 / 603 (0.50%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Obstructive uropathy			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal failure chronic			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Device related infection			
subjects affected / exposed	4 / 603 (0.66%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		

Influenza				
subjects affected / exposed	4 / 603 (0.66%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Appendicitis				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Viral infection				
subjects affected / exposed	2 / 603 (0.33%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Burkholderia cepacia complex sepsis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Clostridium difficile colitis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Disseminated cytomegaloviral infection				

subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Ear infection				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis viral				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
H1N1 influenza				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lung abscess				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Mastoiditis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Mycobacterial infection				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Oesophageal candidiasis				
subjects affected / exposed	1 / 603 (0.17%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Otitis media acute				

subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Peritonitis bacterial			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection viral			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Septic shock			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Viral rash			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Diabetic ketoacidosis			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			

subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fluid overload			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	1 / 603 (0.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	All participants		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 603 (0.00%)		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 June 2007	Dosing changed from 2 times daily to 3 times daily.
10 July 2007	Allowed enrollment for participants who were ineligible for lung transplant for reasons other than FEV1 status.
15 February 2008	Allowed for enrollment of participants who were not responding to current therapy and in the opinion of the investigator had limited therapeutic options.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Per protocol, non-serious adverse events were not collected in this expanded access study.

Notes: